Andon Health earns 17.5 billion CNY a year by selling antigen reagents!

On the evening of January 19, Andon Health Co., Ltd. released the 2022 performance forecast, and it is expected that the company's net profit in 2022 will be 16.5 billion CNY to 17.5 billion CNY, a year-on-year increase of 1715.9% to 1825.95%, and the net profit will be further increased to 16.6 billion yuan to 17.6 billion CNY, a year-on-year increase of 1918.30% to 2039.89%.

For the reasons for the substantial increase in performance, Andon Health said in the prospectus that affected by the pandemic, the demand for COVID-19 epidemic prevention products such as kits sold by the company in the United States increased significantly, the sales revenue of related products increased significantly, and the company's operating performance in 2022 achieved a substantial increase. In addition, the company's operating income mainly comes from overseas sales, mainly settled in US dollars, and the annual average exchange rate of the US dollar against RMB has increased compared with the average exchange rate in 2021, which has a positive impact on the company's net profit.

Andon Health has successively won large orders from the governments of New York, Massachusetts, and other states, and has achieved amazing performance growth. The data shows that from Q1 to Q3 of 2022, Andon Health achieved net profits of 14.312 billion CNY, 932 million CNY and 807 million CNY, respectively, with a year-on-year increase of 37527.35%, 5465.51% and 17452.26%.